Stemrad Scientific Advisory Board member Prof. Michael Levitt wins the Nobel Prize in Chemistry for the development of multiscale models for complex chemical systems.
The use of radioactive material for energy generation in nuclear reactors has become internationally prevalent over the past several decades. This trend is projected to intensify over the next few years due to rising energy prices and global warming. In parallel, hostile regimes and entities are making great efforts to attain nuclear arms or radioactive ‘dirty’ bombs. Thus, western societies are being subjected to an ever growing threat of nuclear catastrophe.
In the event of exposure to large doses of radiation, the immediate life-endangering threat is Acute Radiation Syndrome (ARS), also known as radiation sickness. ARS arises due to the destruction of the individual’s bone marrow, which results in anemia, infections and internal bleeding. StemRad’s solution is to circumvent lethal ARS by offering innovative measures to protect the haematopoietic stem cells (HSCs) present in the bone marrow.